



March 16, 2017

Kansas Senate Public Health and Welfare Committee
The Honorable Chairman Senator Vicki Schmidt
Kansas State Capitol, Room 441-E
Topeka, KS 66612

Chairman Schmidt and Members of the Senate Public Health & Welfare Committee:

My name is Sue Hensley and I work in Government Relations for Pfizer. I am here today to ask you to support House Bill 2107.

HB 2107 simply updates the Kansas Pharmacy Practice Act to allow for the substitution of FDA approved interchangeable biologic products. Passage will result in access to lower cost drugs for patients throughout Kansas.

Pfizer is committed to bringing high-quality biosimilars to patients, providers and payers throughout the United States and the world. I am proud to say that Kansas plays an integral part in this commitment.

Our manufacturing site in McPherson employs more than 1400 colleagues and plays a key role in biosimilars manufacturing. The facility in McPherson has been manufacturing biologics for 30 years. With an established track record in biologic manufacturing, McPherson stands poised to help Pfizer and Kansas enter the biosimilars market in the US.

Thank you for your time today and the opportunity to discuss the importance of HB 2107.

Sincerely,

Sue Hensley

Sue Hensley
US Government Relations
Pfizer Inc.